Transcenta sets board meeting to review interim results, dividend proposalPUBT·1 day ago, 03:35 AM06628-3.80%
Transcenta agrees to sell CDMO assets to WuXi Biologics unit for RMB 190 millionPUBT·Aug 6 at 05:31 PM06628-3.80%WXXWY-0.69%
Transcenta Advances Licensing Deals and Funding Plan to Address Audit DisclaimerTip Ranks·Jul 27 at 06:37 PM06628-3.80%LLY-0.92%
Transcenta Adjusts Board Committees as It Works to Fully Meet HKEX Governance RulesTip Ranks·Jul 27 at 10:08 AM06628-3.80%
Transcenta files board, board committee and disclosure management listPUBT·Jul 27 at 09:54 AM06628-3.80%
Transcenta reverts two Lilly-licensed assets for US$4 million cashPUBT·Jul 7 at 06:23 AM06628-3.80%LLY-0.92%
Transcenta grants 451,500 employee share awards under incentive schemePUBT·Jun 30 at 09:50 AM06628-3.80%
Transcenta appoints Hansen Xu as non-executive director after two independent directors resignPUBT·Jun 30 at 07:25 AM06628-3.80%
TRANSCENTA Ozekibart: Filling the gap in rare cancer treatment, opening up a new blue ocean of commercial value同壁财经·May 25 at 06:31 AM06628-3.80%
Transcenta Gains Boost as Inhibrx’s Ozekibart Data and FDA Filing Strengthen Greater China Cancer FranchiseTip Ranks·May 20 at 06:46 PM06628-3.80%
